Diabete

Photorealistic lab illustration depicting diverse drug-resistant E. coli strains from global diabetic foot infection study, with petri dishes, world map genomics, and scientists analyzing data.

Global genomic study finds highly diverse E. coli strains in diabetic foot infections, including drug-resistant lineages

20 gennaio 2026 Riportato dall'IA Immagine generata dall'IA Verificato

A genomic analysis of Escherichia coli isolated from infected diabetic foot ulcers across 10 countries found no single dominant strain, instead revealing wide genetic diversity and a subset of isolates with markers of multidrug or extensive drug resistance, researchers from King’s College London and the University of Westminster report.

Anvisa amplia indicazioni di Wegovy e Ozempic ai rischi cardiovascolari

L'Anvisa brasiliana ha approvato lunedì 2 febbraio 2026 l'espansione delle indicazioni terapeutiche del semaglutide, principio attivo di Wegovy e Ozempic. Wegovy può ora essere usato per ridurre il rischio di infarti e ictus negli adulti con malattia cardiovascolare e sovrappeso, mentre Ozempic è indicato per il diabete di tipo 2 associato a malattia renale cronica. L'agenzia sta anche esaminando una richiesta per una versione orale di Wegovy.

High blood sugar raises tooth decay risk, Osaka study finds

02 febbraio 2026 Riportato dall'IA

Researchers at the University of Osaka have found that sustained high blood sugar levels raise the risk of tooth decay as sugars transfer from blood to saliva. In a survey of around 60 diabetic and nondiabetic individuals, higher blood sugar was linked to increased glucose and fructose in saliva, along with greater tooth decay and plaque.

Salute

Tufts engineers bacteria to produce rare healthy sugar

Salute

Survey finds limited public awareness of CKM syndrome, which is tied to risk factors common in U.S. adults

Salute

Study links common food preservatives to type 2 diabetes risk

Abbott launches AI feature to aid diabetes meal choices

Health care company Abbott has introduced Libre Assist, a new AI-powered tool within its Libre app, designed to help people with diabetes assess the potential impact of their meals on glucose levels before eating. Users can simply photograph or describe their food to receive predictions and tips. The feature, unveiled at CES 2026, integrates with Abbott's FreeStyle Libre continuous glucose monitors for post-meal insights.

Study finds type 2 diabetes reshapes human heart structure

04 gennaio 2026 Riportato dall'IA

Researchers at the University of Sydney have discovered that type 2 diabetes directly alters the heart's structure and energy production, increasing the risk of heart failure. By examining donated human heart tissue, the team identified molecular changes that stiffen the muscle and disrupt cellular function. These findings, published in EMBO Molecular Medicine, highlight a unique profile in patients with both diabetes and ischemic heart disease.

Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity

Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.

FGF19 hormone activates brain pathway to boost fat burning in obese mice

06 dicembre 2025 Riportato dall'IA Verificato

A study in obese mice has found that the gut-derived hormone FGF19 can signal the brain to increase energy expenditure and activate fat-burning cells. Acting through the hypothalamus and the sympathetic nervous system, this mechanism enhances thermogenesis and cold tolerance and may help guide new treatments for obesity and diabetes.

27 gennaio 2026 01:06